Sernova (TSE:SVA)
TSX:SVA
Want to see TSE:SVA full AI Analyst Report?
SVA Stock Chart & Stats
C$0.15
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.15
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.12 - C$0.21
Previous CloseN/A
Volume71.45K
Average Volume (3M)125.66K
Market Cap
C$52.16M
Enterprise ValueC$65.65M
Total Cash (Recent Filing)C$576.22K
Total Debt (Recent Filing)C$17.55M
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Jun 12, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding347,726,350
10 Day Avg. Volume126,270
30 Day Avg. Volume125,661
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$300.50K
Bulls Say, Bears Say
Bulls Say
Proprietary Cell Pouch PlatformThe Cell Pouch System is a differentiated, implantable platform that supports long-term cell function by creating a vascularized tissue space. That platform-based approach can be a durable competitive advantage if clinical data validate long-term engraftment and multi-indication use, enabling recurring therapy demand and licensing opportunities.
Targets Large Chronic-disease MarketsFocusing on chronic diseases like diabetes addresses structural, high-demand markets where durable therapeutic benefits can replace ongoing care. Successful clinical outcomes could translate into sustained revenue streams and durable market position given the persistent unmet need and large patient populations.
Moderation In Cash Burn And LossesOperating cash outflow and net losses have moderated TTM versus prior years, indicating improving expense control or milestone pacing. This extends runway and reduces near-term financing urgency, giving management more durable time to advance clinical programs and achieve value-driving milestones.
Bears Say
Pre-revenue Business ModelThe company remains pre-revenue, so long-term sustainability depends entirely on future clinical success and external financing rather than operating cash generation. This makes the firm's ability to execute and access capital the primary driver of value over the next several months to years.
Negative Equity And Rising DebtDeeply negative equity and materially higher debt reflect a weakened capital structure that reduces financial flexibility. Elevated leverage increases refinancing and covenant risk, heightens dilution likelihood from future financings, and constrains the company's ability to fund expensive clinical development reliably.
Sustained Negative Cash GenerationPersistent negative operating and free cash flow mean the company will continue to rely on external capital to advance programs. Over the medium term this creates execution risk tied to market financing conditions and increases the probability of dilutive financings if clinical or corporate milestones are delayed.
Sernova News
SVA FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was C$0.12 and its highest was C$0.21 in the past 12 months.
What is Sernova’s market cap?
Sernova’s market cap is C$52.16M.
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Jun 12, 2026 which is in 3 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Mar 13, 2026. The company reported -C$0.01 earnings per share for the quarter, the consensus estimate of -C$0.01 by C$0.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Overvalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate is -0.01.
How many shares outstanding does Sernova have?
Sernova has 347,726,350 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -C$0.01 in its last earnings report, expectations of -C$0.01. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in TSE:SVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sernova
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms for localized cellular immune protection. The Cell Pouch itself is an innovative medical device engineered to establish a highly vascularized tissue environment, crucial for the successful transplantation and engraftment of therapeutic cells. Once integrated, these cells are designed to secrete vital proteins or hormones, providing sustained treatment for a range of severe chronic conditions, including diabetes, hemophilia, and thyroid dysfunction. To bolster its research and development, Sernova maintains a collaborative partnership with AgeX Therapeutics, Inc. focused on generating immune-protected therapeutic cells, and an ongoing research agreement with the University of Miami to further refine its Cell Pouch cell therapy platform. Established in 1998, Sernova Corp. maintains its corporate headquarters in London, Canada.
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Defence Therapeutics
―
Options Prices
Currently, No data available
---